|drug889||Convalescent Plasma Infusion Wiki||1.00|
|D004066||Digestive System Diseases NIH||0.58|
|D005767||Gastrointestinal Diseases NIH||0.58|
|D003141||Communicable Diseases NIH||0.07|
There is one clinical trial.
The COVID-19 outbreak and spread throughout the world now constitutes a global public health emergency. Direct contact between doctors and patients in daily practice bears potential risk of Covid-19 infection, and telemedicine, or non-contact medicine, in this circumstance, offers an ideal solution. Remote controlling capsule endoscopy system for gastric examination was recently developed and applicated in clinical practice.
Description: Maneuvarability of the remote control MCE systemMeasure: Technical success Time: During the procedure
Description: Complete observation of the mucosa (>90% of the mucosa observed) in gastric cardia, fundus, body, angulus, antrum and pylorusMeasure: Clinical success Time: During the procedure
Description: Adverse events during and after the procedureMeasure: Adverse events Time: During and within 2 weeks after the procedure
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports